CTA Regulatory Guidelines and Compliance 1 — Questions and Answers
Question 1: Which international guideline governs Good Clinical Practice (GCP)?
- FDA Part 11
- ISO 9001
- ICH E6(R2) (Correct answer)
- HIPAA
Correct answer: ICH E6(R2)
ICH E6(R2) is the internationally recognized guideline for Good Clinical Practice (GCP), developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. This guideline provides a unified standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials. Adherence to ICH E6(R2) ensures the protection of human subjects and the credibility of data.
Question 2: What is the main purpose of FDA Form 1572?
- To request IRB approval
- To collect patient data
- To enroll new trial sites
- To document investigator responsibilities (Correct answer)
Correct answer: To document investigator responsibilities
FDA Form 1572, also known as the Statement of Investigator, is a commitment form submitted to the FDA by the principal investigator (PI) of a clinical trial. By signing this form, the PI agrees to comply with FDA regulations, the investigational plan, and to ensure that all individuals assisting with the study are informed of their obligations. It formally documents the investigator's critical responsibilities in conducting the trial.
Question 3: What does 21 CFR Part 11 regulate?
- Drug labeling
- Clinical trial protocols
- IRB review procedures
- Electronic records and signatures (Correct answer)
Correct answer: Electronic records and signatures
21 CFR Part 11 is a regulation issued by the U.S. Food and Drug Administration (FDA) that sets forth the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. It ensures the integrity, authenticity, and confidentiality of electronic data used in regulated industries, including clinical trials. This regulation is vital for the use of electronic systems in clinical research.
Question 4: Which regulatory body oversees drug approval in the United States?
- EMA
- WHO
- FDA (Correct answer)
- CDC
Correct answer: FDA
The Food and Drug Administration (FDA) is the primary regulatory body in the United States responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. It reviews and approves new drugs before they can be marketed and sold to the public. The FDA's oversight is critical for consumer protection and drug development.
Question 5: What is a sponsor's key regulatory responsibility in a clinical trial?
- Recruit study subjects
- Administer treatments
- Monitor site staff salaries
- Ensure protocol compliance and data reporting (Correct answer)
Correct answer: Ensure protocol compliance and data reporting
The sponsor of a clinical trial holds ultimate responsibility for the initiation, management, and financing of the study. A key regulatory responsibility is to ensure that the trial is conducted in accordance with the approved protocol, Good Clinical Practice (GCP), and applicable regulations. This includes meticulous oversight of data collection, monitoring, and accurate and timely reporting to regulatory authorities.
Question 6: What is the purpose of an audit in clinical research?
- To discipline non-compliant staff
- To increase participant numbers
- To verify compliance and data accuracy (Correct answer)
- To replace site monitors
Correct answer: To verify compliance and data accuracy
An audit in clinical research is a systematic and independent examination of trial-related activities and documents. Its main purpose is to determine whether the trial was conducted, and data were recorded, analyzed, and accurately reported according to the protocol, sponsor's SOPs, GCP, and regulatory requirements. Audits are crucial for verifying compliance, ensuring data accuracy, and protecting participant rights.
Question 7: Which document must be submitted to the FDA before human trials can begin?
- CSR
- IB
- IND (Correct answer)
- NDA
Correct answer: IND
An Investigational New Drug (IND) application is a submission to the FDA that must be filed and approved before a new drug can be tested in human subjects. The IND provides comprehensive information about the drug, including its manufacturing, preclinical testing results, and the proposed clinical trial protocol. This application demonstrates that it is reasonably safe to proceed with human trials and outlines the plan for further investigation.
Question 8: What is a protocol deviation?
- Addition of a new study site
- Any departure from the approved protocol (Correct answer)
- Updating the informed consent
- Early termination of the trial
Correct answer: Any departure from the approved protocol
A protocol deviation is any instance where the conduct of a clinical trial deviates from the procedures outlined in the approved study protocol. These deviations, whether minor or major, must be documented and assessed for their impact on participant safety and data integrity. Understanding and managing deviations is crucial, as they can affect the validity and reliability of the study results.
Question 9: Why must adverse events be reported to regulatory authorities?
- To delay study timelines
- To maintain FDA approval (Correct answer)
- To allow more participant enrollment
- To reduce monitoring visits
Correct answer: To maintain FDA approval
Reporting adverse events (AEs) to regulatory authorities, such as the FDA, is a mandatory requirement for all clinical trials. This ensures that the regulatory body is continuously informed about the safety profile of the investigational product, allowing them to assess ongoing risks and make informed decisions about the drug's development. Timely and accurate reporting is essential to maintain the study's regulatory approval and ensure public safety.
Which international guideline governs Good Clinical Practice (GCP)?